Advanced search

Find pages with...
Then narrow your results by...

About 71,927 search results

Impairment and cannabis in the workplace

https://www.canada.ca/en/employment-social-development/services/health-safety/cannabis-workplace.html

Jun 20, 2019 ... to prevent the risk of cannabis impairment at work and should note the following employer and employee responsibilities in federally regulated workplaces. For businesses or industries regulated by the province or territory, please refer to provincial and territorial governments. Employers’ responsibilities Employers should: ensure the health and safety of all

Disclosure of confidential business information

https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/request-disclosure-confidential-business-information/disclosure-confidential-business-information.html

Jul 5, 2019 ... a product may pose a serious risk of injury to human health or safety Health Canada published a draft version of this guidance document on March 10, 2016 for public consultation. The draft version was discussed in meetings with industry representatives on April 27, 2016. It was discussed with researchers, health professionals and patient groups on April 28, 2016

Narcotic Control Regulations

https://laws.justice.gc.ca/eng/regulations/C.R.C.,_c._1041/nifnev.html

Jun 3, 2019 ... create a risk to public health or safety, including the risk of a narcotic being diverted to an illicit market or use. Exceptions (2) The Minister must not refuse to issue a licence under paragraph (1)(b) or (i) if the applicant meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public

Regulatory roadmap for biologic (Schedule D) drugs in Canada

https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/regulatory-roadmap-for-biologic-drugs.html

Jul 15, 2019 ... Use New Drug Submission (EUSNDS) A Notice of Compliance (NOC) and a Drug Identification Number (DIN) are issued by Health Canada when the: evidence supports the safety, efficacy and quality claims for an NDS or an SNDS benefits outweigh the risks The NOC and the DIN indicate that Health Canada has approved the drug for sale in Canada. A drug in dosage form

Benzodiazepines and Other Targeted Substances Regulations

https://laws.justice.gc.ca/eng/regulations/SOR-2000-217/page-12.html

Jun 3, 2019 ... kit if the Minister determines that the test kit is being used for a purpose other than a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose and, after considering the nature and extent of that other purpose, concludes that it poses a risk to security, public health or safety, including the risk of the targeted

Document: Consultation on Potential Market for Cannabis Health Products that would not Require Practitioner Oversight

https://www.canada.ca/en/health-canada/programs/consultation-potential-market-cannabis/document.html

Jun 19, 2019 ... market for CHPs, key parameters of a proposed regulatory framework for CHPs are outlined below. See Table 1 (after section 3.6) for a description of the proposed category of CHPs, and comparisons to existing product categories. 3.1 Legal Oversight Given the public health and safety risks of cannabis, certain controls under the CA would still apply to CHPs

Draft Screening Assessment Acetic acid

https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-substances/draft-screening-assessment-acetic-acid.html

Jul 19, 2019 ... 2018). f Personal communication, email from Consumer Product Safety Directorate, Health Canada, to the Existing Substances Risk Assessment Bureau, Health Canada, dated June 20, 2018; unreferenced g Personal communication, email from Pest Management Regulatory Agency, Canada, to the Existing Substances Risk Assessment Bureau, Health Canada, dated July 25, 2018

Guidance - Use of Positron-emitting Radiopharmaceuticals in Basic Clinical Research

https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/positron-emitting-radiopharmaceutical-profile/guidance-document.html

Jul 18, 2019 ... and information about any potential risk to the health of the study subjects or other persons. 2.2 Section C.03.303 Limits on the Distribution of the Study Drugs “No person shall sell or import a study drug unless all of the following requirements are met: the study drug is for use only in a study; the study drug has been previously tested in human subjects and its safety

Draft screening assessment - Methane, dimethoxy- (dimethoxymethane)

https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-substances/draft-screening-assessment-methane-dimethoxy-dimethoxymethane.html

Jul 19, 2019 ..., dimethoxymethane is used as a solvent in certain cosmetic products for hair styling and hair conditioning (emails from the Consumer Product Safety Directorate, Health Canada, to the Existing Substances Risk Assessment Bureau, Health Canada, 2018; unreferenced). Dimethoxymethane may also be used as an ingredient in certain cleaners used in Canadian food processing

Nuclear Energy and Public Health: Health Risks of Chronic Exposure to Low Levels of Tritium - Canadian Nuclear Safety Commission

http://www.nuclearsafety.gc.ca/eng/resources/research/technical-papers-and-articles/2018/risks-of-chronic-exposure-to-low-levels-of-tritium.cfm

Dec 27, 2018 ...Nuclear Energy and Public Health: Health Risks of Chronic Exposure to Low Levels of Tritium Abstract of the article published in: Science (August 27, 2018) Author(s):           Guéguen, Y.; Priest, N.D.; Dublineau, I.; Bannister, L.; Benderitter, M.; Durand, C.; Ebrahimian, T.; Grégoire, E.; Grison, S.; Ibanez, C.; Legendre, A.; Lestaevel, P.; Roch-Lefèvre

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: